Should you buy Cardinal Health stock now?
Yes, the technical signal for Cardinal Health is currently BUY. Cardinal Health trades at $234.49 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 2.342 with rising momentum (signal: 1.905); RSI is at 62.2 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $252.40 points to 7.6% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Cardinal Health stock?
The average analyst price target for Cardinal Health is $252.40. The current price is $234.49, which gives an upside of 7.6%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $227.16 and $277.64.
Is Cardinal Health a dividend stock?
Yes, Cardinal Health is a dividend stock with a dividend yield of 0.87%. The latest dividend was $0.52 per share. The latest ex-dividend date (traded without the dividend) was 7/1/2026. The payout ratio is 24.5%, which is considered sustainable. The next dividend payment is scheduled for 7/15/2026.
When does Cardinal Health pay a dividend in 2026?
Cardinal Health pays its next dividend on 7/15/2026. The latest dividend was $0.52 per share with an ex-dividend date of 7/1/2026. The dividend yield is 0.87%. The payout ratio of 24.5% points to a sustainable dividend with room to grow.
What is the risk of Cardinal Health stock?
Cardinal Health is rated as a stock with moderately low risk. the annual standard deviation is 30.6%, which classifies the stock as moderately low risk.
Is Cardinal Health overvalued?
Cardinal Health is considered fairly valued – the price is close to the analyst price target. Cardinal Health has the following valuation ratios: a P/E ratio of 36.0 (highly valued), a P/S ratio of 0.2, a P/B ratio of 16.1. The stock trades close to the analyst price target and is considered fairly valued.
Is Cardinal Health overbought?
No, Cardinal Health is not overbought. RSI is at 62.2 (neutral zone). The technical indicators show: RSI is at 62.2 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 2.0% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Cardinal Health earnings report?
Cardinal Health reports its next earnings on August 11, 2026. The stock currently trades at $234.49. With a P/E ratio of 36.0, the market will be watching closely whether earnings meet expectations.
Is Cardinal Health shorted?
Yes, Cardinal Health is shorted with 3.3% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Cardinal Health stock?
No, insiders are not buying Cardinal Health shares – they are net sellers. Across the last 20 reported transactions, the split is 2 purchases and 18 sales, with a net 29,513,436 $ sold. Active sellers include Greene Michelle D., Alt Aaron E, Hall Patricia Hemingway and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Cardinal Health a good stock?
Based on our total score, Cardinal Health is rated as a mediocre stock with a total score of 56 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 46/100, Quality: 36/100, Momentum: 85/100. In addition: a dividend of 0.87%; technical signal: Strong Buy. Whether Cardinal Health is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Cardinal Health stock?
The outlook for Cardinal Health based on current data: the average analyst price target is $252.40 (+7.6%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on 8/11/2026, which can move the price; the P/E ratio is 36.0 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Cardinal Health stock moving?
Cardinal Health is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Cardinal Health go?
The average analyst price target for Cardinal Health is $252.40, which corresponds to a potential gain of 7.6% from the current price of $234.49. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Cardinal Health fall?
We lack enough history to give a specific floor for Cardinal Health. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Cardinal Health do?
Cardinal Health driver en stor forretning inden for sundhedsydelser og produkter, især i USA, men også i Europa og Asien. De tjener primært penge på at distribuere medicin og udstyr.
Virksomheden er delt i to: Farmaceutisk og Medicinsk. Den farmaceutiske del sælger både mærke... The company belongs to the Sundhed sector, more specifically the Medicinsalg industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Cardinal Health as an investment.
Did Cardinal Health raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Cardinal Health. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Cardinal Health making money or losing money?
Yes, Cardinal Health is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 0.6% — which is modest. The operating margin (profit before interest and taxes) is 1.4%. At a P/E ratio of 36.0, you currently pay 36.0 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Cardinal Health go bankrupt?
The bankruptcy risk of Cardinal Health is rated as elevated. Altman Z2 (a model for assessing financial distress) is -0.15 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Cardinal Health have a lot of debt?
Yes, Cardinal Health has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Cardinal Health service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 4.9x, and net debt equals 1.3 years of earnings (EBITDA).
